Our Management board currently consists of seven members. The international composition and the varied responsibilities reflect our global operations.
Rice Powell (60) is chief executive officer and chairman of the management board effective January 1, 2013. Prior to that, he was vice chairman of the management board and member of the management board responsible for the region North America from 2010 to 2012. He joined Fresenius Medical Care in 1997 and was appointed to the company's management board and Co-CEO of Fresenius Medical Care North America in January 2004. He has over 36 years of experience in the healthcare industry. From 1978 to 1996, he held various positions, among others at Baxter International Inc. and Biogen Inc. in the U.S.
Michael Brosnan (60) was appointed chief financial officer on January 1, 2010. Previously, he served as chief financial officer of Fresenius Medical Care North America for seven years. He joined the company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to joining the company, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG.
Roberto Fusté (63) is chief executive officer for Asia-Pacific. After completing his studies in Economic Sciences at the University of Valencia, Spain, he founded the company Nephrocontrol S.A. in 1983. After Nephrocontrol was acquired by the Fresenius Group in 1991, he held several senior positions within the company in the Latin America and Asia-Pacific regions, among others. He was appointed to the management board of Fresenius Medical Care in 1999.
Ronald Kuerbitz (55) is chief executive officer for North America effective January 1, 2013. He joined Fresenius Medical Care in 1997. Before being appointed to the company's management board he served as executive vice president for Market Development and Administration for Fresenius Medical Care North America. He has more than 20 years of experience in the health care field, having held positions in law, compliance, business development, government affairs and operations. He is a graduate of Albion College and received his juris doctor degree from the Yale Law School.
Dr. Olaf Schermeier
Research and Development
Dr. Olaf Schermeier (42) was appointed chief executive officer for Global Research and Development on March 1, 2013. Previously, he served as president of global R&D for Draeger Medical, Lübeck, Germany. Dr. Schermeier has many years of experience in various areas of the health care industry, among others at Charité-clinic and Biotronik, Germany. He holds a doctorate degree (PhD) in Computer Science from the Technical University of Berlin, Germany and graduated from the University of Hannover, Germany in Electrical Engineering.
Kent Wanzek (56) was appointed chief executive officer for Global Manufacturing Operations on January 1, 2010. From 2004 onwards, he was in charge of North American operations for the Renal Therapies Group at Fresenius Medical Care North America. Prior to joining the company in 2003, he held several senior executive positions at Philips Medical Systems, Perkin Elmer and Baxter Healthcare Corporation, among others.
Europe, Middle East and Africa, and labor relations director Germany
Dominik Wehner (46) was appointed chief executive officer for Europe, Middle East and Africa (EMEA) on April 1, 2014. He has also been appointed labor relations director for Germany. He began his career at Fresenius Medical Care in 1994 as junior sales manager. Before being appointed to the company's management board he served as executive vice president responsible for the regions Eastern Europe, Middle East and Africa as well as Renal Pharma Europe, Middle East, Africa and Latin America EMEALA and P. O. I. (People, Organizational Change and Implementation) EMEALA. He also serves on the Vifor Fresenius Medical Care Renal Pharma Ltd. board of directors.